Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
FIBROGEN INC (FGEN) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 8-K Quarterly results
Docs: "FibroGen Reports Second Quarter 2023 Financial Results • Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network Precision PromiseSM Phase 2/3 study in metastatic pancreatic cancer • Robust roxadustat volume growth of over 40% in China • Entered into exclusive license for FOR46, a first-in-class CD46-targeting antibody-drug conjugate for the treatment of metastatic castration-resistant prostate cancer • Implemented cost reduction plan extending cash runway into 2026 • Thane Wettig appointed Interim CEO"
05/08/2023 8-K Quarterly results
Docs: "FibroGen Reports First Quarter 2023 Financial Results • Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value • Entered Into Exclusive License for FOR46 with Fortis Therapeutics"
02/27/2023 8-K Quarterly results
Docs: "FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results • Topline Data from Five Pivotal Phase 3 Trials in 2023 • Total Company Revenue $140.7 Million in 2022 • Continued Strong Roxadustat Volume Growth in China"
11/07/2022 8-K Quarterly results
Docs: "FibroGen Reports Third Quarter 2022 Financial Results • Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024 • Completed enrollment of MATTERHORN Phase 3 study of roxadustat in patients with anemia of myelodysplastic syndromes with topline data expected 1H 2023 • Strong roxadustat volume growth in China of over 80% vs 3Q 2021 • Announced non-dilutive royalty monetization transaction with NovaQuest for $50 million of capital secured by 22.5% of roxadustat royalty revenue in the Astellas territories"
08/08/2022 8-K Quarterly results
05/09/2022 8-K Quarterly results
02/28/2022 8-K Quarterly results
11/09/2021 8-K Quarterly results
Docs: "FibroGen Reports Third Quarter 2021 Financial Results • Roxadustat Receives EU approval for Patients with Anemia of CKD, triggering a $120M milestone payment from Astellas • Roxadustat net product revenue in China of $13.4 million, on a US GAAP basis"
08/09/2021 8-K Quarterly results
Docs: "FibroGen Reports Second Quarter 2021 Financial Results"
05/10/2021 8-K Quarterly results
03/01/2021 8-K Quarterly results
11/05/2020 8-K Quarterly results
Docs: "FibroGen Reports THIRD Quarter 2020 Financial Results - Strong third Quarter China Roxadustat Net Sales of $22.7 million - - Conference Call Today at 5:00 p.m. Eastern Time/2:00 p.m. Pacific Time -"
08/06/2020 8-K Quarterly results
05/07/2020 8-K Quarterly results
03/02/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
08/08/2019 8-K Quarterly results
Docs: "FIBROGEN REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS"
05/09/2019 8-K Quarterly results
Docs: "FIBROGEN REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS"
02/27/2019 8-K Quarterly results
11/08/2018 8-K Quarterly results
Docs: "FIBROGEN REPORTS third QUARTER 2018 FINANCIAL RESULTS —Roxadustat New Drug Applications under Review in China and Japan— — Phase 3 Clinical Trials in IPF and Pancreatic Cancer to Initiate in First Quarter 2019"
05/09/2018 8-K Quarterly results
Docs: "FIBROGEN REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS"
02/27/2018 8-K Quarterly results
Docs: "FibroGen Reports Fourth QUARTER and FULL YEAR 2017 Financial Results Roxadustat U.S. Phase 3 Program in CKD Anemia Enrollment Completion and Data Readout in 2018"
11/08/2017 8-K Quarterly results
Docs: "FIBROGEN REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS"
08/07/2017 8-K Quarterly results
Docs: "FIBROGEN REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS"
05/09/2017 8-K Form 8-K - Current report
03/01/2017 8-K Form 8-K - Current report
11/08/2016 8-K Quarterly results
Docs: "FibroGen Reports Financial Results for the Third Quarter of 2016 and Provides Corporate Update – Completes Enrollment of Roxadustat Phase 3 Studies in China for Anemia in CKD –"
08/08/2016 8-K Form 8-K - Current report
05/09/2016 8-K Quarterly results
Docs: "FibroGen Reports Financial Results for the First Quarter of 2016 Continued Progress in Roxadustat Phase 3 Studies; Promising Interim Pancreatic Cancer Data –Webcast Conference Call Scheduled for 4:30pm EST Today–"
02/29/2016 8-K Quarterly results
Docs: "FibroGen Announces Fiscal 2015 Financial Results"
11/12/2015 8-K Quarterly results
Docs: "FibroGen Announces Third Quarter 2015 Financial Results FibroGen Share of US / EU Roxadustat Development Cost Obligations Expected to Be Reached in Fourth Quarter"
08/13/2015 8-K Quarterly results
Docs: "FibroGen Announces Second Quarter 2015 Financial Results",
"FibroGen Announces Second Quarter 2015 Financial Results"
05/12/2015 8-K Quarterly results
Docs: "FibroGen Announces First Quarter 2015 Financial Results"
03/26/2015 8-K Quarterly results
Docs: "FibroGen Announces 2014 Financial Results and Provides Corporate Update"

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy